The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

A new monthly weight loss drug, MariTide, helped people shed up to 20% of body weight in a Phase 2 trial—comparable to Wegovy ...

Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...